TCW Group Inc. Boosts Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Key Points

• TCW Group Inc. increased its stake in Teva Pharmaceutical Industries by 23.9%, owning 135,202 shares valued at approximately $2.08 million as of the latest SEC filing.
• Teva's stock recently traded at $16.51, with a market cap of $18.93 billion, and has been rated as a "buy" by several analysts with an average target price of $24.71.
• In executive transactions, EVP Matthew Shields sold 6,206 shares at an average price of $17.02, reducing his ownership by 38.32% to 9,989 shares.

TCW Group Inc. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 23.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,202 shares of the company's stock after purchasing an additional 26,105 shares during the quarter. TCW Group Inc.'s holdings in Teva Pharmaceutical Industries were worth $2,078,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth about $39,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $44,000. Compagnie Lombard Odier SCmA acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Finally, Versant Capital Management Inc grew its holdings in Teva Pharmaceutical Industries by 437.8% in the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after purchasing an additional 4,312 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 0.0%

Teva Pharmaceutical Industries stock traded down $0.01 during trading on Tuesday, reaching $16.51. 18,128,250 shares of the company were exchanged, compared to its average volume of 9,744,226. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a market capitalization of $18.93 billion, a P/E ratio of -14.35, a PEG ratio of 0.97 and a beta of 0.60. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The stock's 50 day simple moving average is $16.92 and its two-hundred day simple moving average is $16.70.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the previous year, the business earned $0.48 earnings per share. The company's revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Bank of America raised their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Finally, UBS Group dropped their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of "Buy" and a consensus target price of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.